UiPath Inc. (NYSE:PATH - Get Free Report)'s share price rose 4.7% during trading on Monday . The company traded as high as $20.17 and last traded at $20.12. Approximately 2,296,052 shares changed hands during mid-day trading, a decline of 72% from the average daily volume of 8,205,011 shares. The stock had previously closed at $19.22.
Wall Street Analyst Weigh In
Several research analysts have issued reports on PATH shares. JPMorgan Chase & Co. raised shares of UiPath from a "neutral" rating to an "overweight" rating and raised their price objective for the stock from $22.00 to $28.00 in a research report on Thursday, March 14th. Morgan Stanley boosted their price target on UiPath from $17.00 to $25.00 and gave the company an "equal weight" rating in a research report on Thursday, March 14th. BMO Capital Markets increased their price objective on UiPath from $24.00 to $28.00 and gave the stock a "market perform" rating in a research report on Thursday, March 14th. Needham & Company LLC reissued a "buy" rating and issued a $30.00 target price on shares of UiPath in a report on Wednesday, March 20th. Finally, Mizuho increased their price target on UiPath from $22.00 to $25.00 and gave the stock a "neutral" rating in a report on Thursday, March 14th. Nine analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $27.41.
View Our Latest Report on PATH
UiPath Trading Up 3.1 %
The firm has a 50 day moving average of $21.35 and a two-hundred day moving average of $21.87. The stock has a market capitalization of $11.27 billion, a PE ratio of -118.35 and a beta of 1.01.
UiPath (NYSE:PATH - Get Free Report) last announced its quarterly earnings results on Wednesday, March 13th. The healthcare company reported $0.06 earnings per share for the quarter, beating analysts' consensus estimates of ($0.04) by $0.10. UiPath had a negative return on equity of 3.29% and a negative net margin of 6.87%. The business had revenue of $405.25 million during the quarter, compared to analysts' expectations of $383.32 million. Equities research analysts forecast that UiPath Inc. will post -0.04 EPS for the current year.
Insider Buying and Selling at UiPath
In related news, CFO Ashim Gupta sold 40,000 shares of UiPath stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $21.66, for a total transaction of $866,400.00. Following the completion of the transaction, the chief financial officer now directly owns 660,762 shares in the company, valued at approximately $14,312,104.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 96,000 shares of company stock valued at $2,023,440 over the last quarter. Corporate insiders own 31.03% of the company's stock.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in PATH. Norges Bank purchased a new position in UiPath during the fourth quarter worth about $165,749,000. Vanguard Group Inc. grew its position in UiPath by 7.6% during the third quarter. Vanguard Group Inc. now owns 37,750,773 shares of the healthcare company's stock valued at $645,916,000 after acquiring an additional 2,673,718 shares during the period. Artisan Partners Limited Partnership acquired a new stake in UiPath during the fourth quarter worth about $48,267,000. Glenmede Trust Co. NA grew its holdings in shares of UiPath by 3,273.3% during the 3rd quarter. Glenmede Trust Co. NA now owns 1,564,985 shares of the healthcare company's stock worth $26,777,000 after purchasing an additional 1,518,592 shares during the period. Finally, Vestmark Advisory Solutions Inc. acquired a new stake in UiPath during the 4th quarter worth approximately $15,543,000. Institutional investors and hedge funds own 62.50% of the company's stock.
About UiPath
(
Get Free Report)
UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider UiPath, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UiPath wasn't on the list.
While UiPath currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
